In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “SITC Living Guidelines” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum.
Rapid Update v1.1 Summary
The information below provides an overview of update v1.1 to the "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer" published in Journal for ImmunoTherapy of Cancer (JITC).
- The FDA granted accelerated approval for retifanlimab (anti-PD-1 ICI) for the treatment of adult patients with metastatic or recurrent locally advanced MCC in March 2023. The NMSC CPG was updated in the following locations: "Introduction," "Merkel Cell Carcinoma," "Recommended Immunotherapies for MCC," "FDA-Approved ICI agents for NMSC," "NMSC Landmark Clinical Trial Data Leading to FDA Approvals for ICIs for MCC," and "Novel Strategies and Promising Future Directions."
- Data have been reported demonstrating efficacy with neoadjuvant anti-PD-1 ICI therapy prior to curative-intent surgery in patients with CSCC. Based on these practice-changing data, the NMSC CPG was updated in the following locations: "Recommended Immunotherapies for CSCC," and "Novel Strategies and Promising Future Directions for CSCC."
- Data have been reported demonstrating efficacy combining an anti-PD-(L)1 ICI with an anti-CTLA-4 ICI for patients with advanced MCC. Based on these practice-changing data, the NMSC CPG was updated in the following locations: "Merkel Cell Carcinoma," "Recommended Immunotherapies for MCC," and "Novel Strategies and Future Directions for CSCC."
How to View the Living Guideline Rapid Update
Through the use of an innovative technology, rapid updates are swiftly integrated into our existing published guidelines in a clear and concise manner. An overlay system highlights affected content and provides new text reflecting the updated Expert Panel guidance as well as important supporting information, data, and references, as applicable. These rapid updates show the progression of the changes by using a version numbering system that accompanies each new posted update.
- View Update v1.1 as an overlay to the original publication in JITC
For More Information
- SITC NMSC CPG – Overview of all available updates and companion guideline educational offerings for this guideline
- SITC Guidelines Program – Listing of all published guidelines in the SITC CPG catalogue and more about the SITC Living Guidelines rapid update
- Follow us on social media – #SITCGuidelines on “X” and LinkedIn
- Questions – Contact a member of the SITC guideline development staff at scientificresources@sitcancer.org